9497 related articles for article (PubMed ID: 1859902)
1. [Brain metastases of malignant melanomas].
Boaziz C; Breau JL; Morere JF; Israël L
Bull Cancer; 1991; 78(4):347-53. PubMed ID: 1859902
[TBL] [Abstract][Full Text] [Related]
2. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
3. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
4. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
5. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
6. [The blood-brain barrier: implications for chemotherapy in brain tumors].
Boaziz C; Breau JL; Morère JF; Israël L
Pathol Biol (Paris); 1991 Oct; 39(8):789-95. PubMed ID: 1762838
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Walker MD; Green SB; Byar DP; Alexander E; Batzdorf U; Brooks WH; Hunt WE; MacCarty CS; Mahaley MS; Mealey J; Owens G; Ransohoff J; Robertson JT; Shapiro WR; Smith KR; Wilson CB; Strike TA
N Engl J Med; 1980 Dec; 303(23):1323-9. PubMed ID: 7001230
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of mustoforan in management of malignant glioma].
Kobiakov GL
Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
[No Abstract] [Full Text] [Related]
9. Survival response of malignant gliomas to radiotherapy with or without BCNU or methyl-CCNU chemotherapy at the University of Kentucky Medical Center.
Chin HW; Young AB; Maruyama Y
Cancer Treat Rep; 1981; 65(1-2):45-51. PubMed ID: 7013978
[TBL] [Abstract][Full Text] [Related]
10. Nitrosoureas in the management of disseminated malignant melanoma.
Ahmann DL
Cancer Treat Rep; 1976 Jun; 60(6):747-51. PubMed ID: 782696
[TBL] [Abstract][Full Text] [Related]
11. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Eyre HJ; Eltringham JR; Gehan EA; Vogel FS; Al-Sarraf M; Talley RW; Costanzi JJ; Athens JW; Oishi N; Fletcher WS
Cancer Treat Rep; 1986 Sep; 70(9):1085-90. PubMed ID: 3017551
[TBL] [Abstract][Full Text] [Related]
13. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Ulrich J; Gademann G; Gollnick H
J Neurooncol; 1999 Jun; 43(2):173-8. PubMed ID: 10533730
[TBL] [Abstract][Full Text] [Related]
14. [Study of the clinical pharmacokinetics of fotemustine in various tumor indications].
Lokiec F; Beerblock K; Deloffre P; Lucas C; Bizzari JP
Bull Cancer; 1989; 76(10):1063-9. PubMed ID: 2635634
[TBL] [Abstract][Full Text] [Related]
15. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
16. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
Merimsky O; Inbar M; Reider-Groswasser I; Chaitchik S
Eur J Cancer; 1991; 27(8):1066. PubMed ID: 1832900
[No Abstract] [Full Text] [Related]
17. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic strategies and systemic treatment of brain melanoma metastases].
Durando X; Mansard S; Daste A; Gimbergues P; Brocard L; Magné N; Thivat E
Bull Cancer; 2013 Jan; 100(1):23-8. PubMed ID: 22889847
[TBL] [Abstract][Full Text] [Related]
19. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
[No Abstract] [Full Text] [Related]
20. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
[No Abstract] [Full Text] [Related]
[Next] [New Search]
